Tests guselkumab to prevent arthritis in people with psoriasis
Tests guselkumab against placebo in adults with psoriasis at high risk of arthritis.
Plain-language title generated from the registry record
Registry title: Multi-Center PAMPA Study
Key facts
- Where
- St. John's and Toronto, CanadaSee the 2 sites
- Phase
- Phase 4
Where in Canada
- Memorial UniversitySt. John's, CanadaTaking people
- Women's College Research Institute, University of TorontoToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- NYU Langone Health
- Trial code
- NCT05004727
- Record updated
- 30 March 2026
- Original description
This is a multi-center (North-America), randomized, double-blind, placebo-controlled, wait-list, interventional, preventive trial of guselkumab in high-risk psoriasis patients compared to non-biologic standard of care.Read full original descriptionShow less
Preventing Arthritis in a Multi-Center Psoriasis At-Risk Cohort
This is a multi-center (North-America), randomized, double-blind, placebo-controlled, wait-list, interventional, preventive trial of guselkumab in high-risk psoriasis patients compared to non-biologic standard of care.
The primary objective of the proposed trial will be to test the hypothesis that a prolonged, unresolved skin inflammation coupled with musculoskeletal power-doppler ultrasound (MSKPDUS) abnormalities driven by IL-23 increase the risk for transition into PsA and that an intervention that targets one of these pivotal molecules (i.e., Guselkumab) will:
1. Diminish MSKPDUS findings at 24 weeks, and 2. Significantly reduce or prevent the emergence of synovio-enthesial phenotype at year 2.
Inclusion: 18 years old or older; Both male \& female; Psoriasis diagnosis (per dermatologist) for at least 2 years (in at least 30% of participants); Willing and able to provide informed consent; Fulfillment of HR-PsO criteria (Psoriasis (PsO) patients will meet the definition of HR if they fulfill the following criteria: a) PsO duration >2 years and Psoriasis Body Surface Area (BSA) >3% and positive imaging findings in MSKPDUS defined as a RM-PsASon score of >3.36.
Exclusion: Current systemic immunosuppressive medication use (i.e., methotrexate, apremilast) at the time of enrollment or biologic therapy (ever); Current active malignancy; History of symptomatic polyarticular OA or other joint conditions (such as RA, gout, etc) that may impair the ability to assess for PsA development; Conditions where initiation of guselkumab is prohibited in the prescribing information, including clinically important active infection and untreated latent tuberculosis; Known hypersensitivity to the study agent; Evidence of inflammatory joint pain, enthesitis and/or dactylitis on exam; RA seropositivity (mid-high RF/ACPA titers).